title: A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
abstract: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Imatinib mesylate is recommended as adjuvant therapy for GIST after surgical resection. However, drug-related adverse events are common. A 74-year-old female with metastatic GIST who was managed with imatinib experienced severe adverse events, including skin rashes, tremor, and alopecia, etc. The imatinib dose was reduced and the size of the metastatic GIST continued to decrease and adverse events showed significant improvement.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Bo Hyun
authors.initials: BH
authors.lastname: Jang
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Byung Wook
authors.initials: BW
authors.lastname: Kim
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Keun Joon
authors.initials: KJ
authors.lastname: Lim
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Boo Gyoung
authors.initials: BG
authors.lastname: Kim
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Sung Min
authors.initials: SM
authors.lastname: Park
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Joon Sung
authors.initials: JS
authors.lastname: Kim
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Jeong Seon
authors.initials: JS
authors.lastname: Ji
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary.
authors.forename: Hwang
authors.initials: H
authors.lastname: Choi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005076:Exanthema / Q000209:etiology; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects / Q000627:therapeutic use*; D007150:Immunohistochemistry; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit
keywords: Gastrointestinal stromal tumors; Imatinib